Benjamin H. Mullish

St Mary's Hospital
London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 169 publications

Defining 'gut health': a leap forward, but still some road to travel.

Defining 'gut health': a leap forward, but still some road to travel.

Journal: Nature reviews. Gastroenterology & hepatology

Published: March 18, 2026

Efimosfermin, a Fibroblast Growth Factor 21 Analogue for Metabolic Dysfunction-Associated Steatohepatitis.

Efimosfermin, a Fibroblast Growth Factor 21 Analogue for Metabolic Dysfunction-Associated Steatohepatitis.

Journal: Gastroenterology

Published: March 01, 2026

Efimosfermin, a fibroblast growth factor 21 analogue, for metabolic dysfunction-associated steatohepatitis.

Efimosfermin, a fibroblast growth factor 21 analogue, for metabolic dysfunction-associated steatohepatitis.

Journal: Gastroenterology

Published: March 01, 2026

A global evaluation of the use of faecal microbiota transplant (FMT).

A global evaluation of the use of faecal microbiota transplant (FMT).

Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Published: February 06, 2026

Recent advances in our understanding of the gut microbiome: an analysis from the Gut Microbiota for Health Expert Panel of the British Society of Gastroenterology.

Recent advances in our understanding of the gut microbiome: an analysis from the Gut Microbiota for Health Expert Panel of the British Society of Gastroenterology.

Journal: Gut

Published: January 29, 2026

Disordered Bile Acid Metabolism in Alcohol-Related Hepatitis.

Disordered Bile Acid Metabolism in Alcohol-Related Hepatitis.

Journal: Alimentary pharmacology & therapeutics

Published: January 09, 2026

Improving Efficacy Without Increasing Side Effects? Exploring the Impact of a Novel GLP-1-Glucagon Dual Receptor Agonist Upon Metabolic Dysfunction-Associated Steatohepatitis.

Improving Efficacy Without Increasing Side Effects? Exploring the Impact of a Novel GLP-1-Glucagon Dual Receptor Agonist Upon Metabolic Dysfunction-Associated Steatohepatitis.

Journal: Gastroenterology

Published: January 08, 2026

The use of pharmacotherapies in non-cirrhotic metabolic dysfunction-associated steatohepatitis: a UK expert consensus.

The use of pharmacotherapies in non-cirrhotic metabolic dysfunction-associated steatohepatitis: a UK expert consensus.

Journal: The lancet. Gastroenterology & hepatology

Published: December 21, 2025

Efficacy and safety of microbiota-targeted therapeutics in autoimmune and inflammatory rheumatic diseases: protocol for a systematic review and meta-analysis of randomised controlled trials.

Efficacy and safety of microbiota-targeted therapeutics in autoimmune and inflammatory rheumatic diseases: protocol for a systematic review and meta-analysis of randomised controlled trials.

Journal: BMJ open

Published: December 15, 2025

Disease phenotype affects treatment of late-onset inflammatory bowel disease: Analysis of a large UK cohort.

Disease phenotype affects treatment of late-onset inflammatory bowel disease: Analysis of a large UK cohort.

Journal: Inflammatory bowel diseases

Published: November 19, 2025

Microbiota transplants: the concept of 'microbiome mismatching' explored.

Microbiota transplants: the concept of 'microbiome mismatching' explored.

Journal: Signal transduction and targeted therapy

Published: September 05, 2025

The emerging role of the gut microbiota in vaccination responses.

The emerging role of the gut microbiota in vaccination responses.

Journal: Gut microbes

Published: August 30, 2025

Showing 1-12 of 169

Last Updated: 09/26/2026